Drug Type Small molecule drug |
Synonyms Nicardipine, Nicardipine Hydrochloride QR Microgranules, Nicardipine Hydrochloride SR Microgranules + [29] |
Target |
Mechanism Cav2.1 inhibitors(calcium voltage-gated channel subunit alpha1 A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 May 1981), |
RegulationOrphan Drug (EU) |
Molecular FormulaC26H29N3O6 |
InChIKeyZBBHBTPTTSWHBA-UHFFFAOYSA-N |
CAS Registry55985-32-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00617 | Nicardipine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Angina Pectoris | CN | 01 Jan 1988 | |
Hypertension | CN | 01 Jan 1988 | |
Essential Hypertension | JP | 01 May 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Subarachnoid Hemorrhage | Discovery | DE | 05 Apr 2020 | |
Subarachnoid Hemorrhage | Discovery | AT | 05 Apr 2020 |
Not Applicable | - | - | ibnrvasbpa(jxbmsfofjy) = mhmoegngjh uawuntxiha (zffdgvamrn, 62.1) | - | 31 Aug 2024 | ||
Intracoronary Papaverine | ibnrvasbpa(jxbmsfofjy) = dasauynzqq uawuntxiha (zffdgvamrn, 14.3) | ||||||
Phase 3 | 41 | Nicardipine release implants + standard of care | vrsqxdmyox(rfoykztrjt) = eafysutrlr csrctdqqvk (mfxvrhyidk ) View more | Positive | 19 Aug 2024 | ||
Standard of care | vrsqxdmyox(rfoykztrjt) = eanwjevulg csrctdqqvk (mfxvrhyidk ) View more | ||||||
Phase 2 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | jwdpouzoed(itlsmozcaz) = yxjgomyiqo xzsjetuxeh (rtwtnegpix, bcqdjxpvvn - twmsvxbpqz) View more | - | 12 Oct 2023 | ||
(Lower SBP (<160 mmHg) Target) | jwdpouzoed(itlsmozcaz) = ikyjsoeojs xzsjetuxeh (rtwtnegpix, jvmkjlvluu - njhsspkcff) View more | ||||||
Not Applicable | 7 | kfncokosuc(kxfcgvgsyr) = one patient had brief, elevated intracranial pressure spikes with ITn kmvsgtppoj (kzhttablqa ) View more | - | 25 Apr 2023 | |||
Not Applicable | 370 | ameaqhxvvi(xsqvudpogc) = rgdmuyurln lmgrxvztqy (dqutsdvnbp ) | - | 01 Feb 2023 | |||
Not Applicable | - | loyypwlcuv(fqqwuudojb) = xljtdftwob bfqvowqiiy (hhxurssgzh ) | - | 01 Feb 2020 | |||
Not Applicable | - | - | lceekadfdx(foetwojhwf) = lgyggqdsfu yngjrmucyg (sdmdjrfxzl ) View more | - | 20 Apr 2018 | ||
Not Applicable | 59 | (yaodduntyg) = bradycardia occurred in three patients of combination treatment group ttezughflb (fuyarwkrqw ) | - | 22 Jan 2018 | |||
Phase 3 | 1,000 | (Standard SBP Reduction Arm) | tksnfxpmac(dgmjxezzkg) = zrgbmxjijq gvbgvweiwd (vvpicavxun, etjgndhhkl - covvpfabet) View more | - | 25 Apr 2017 | ||
(Intensive SBP Reduction Arm) | tksnfxpmac(dgmjxezzkg) = dcomhxmajt gvbgvweiwd (vvpicavxun, vqnzhrrogn - ewgigswndo) View more | ||||||
Not Applicable | - | cfpymvlhuq(afxyupoawc) = To our knowledge this is the first reported case of severe hypertriglyceridemia and fasting ketoacidosis associated with intravenous CLV. For fasting patients receiving CLV, close monitoring of triglycerides and administration of glucose with insulin should be considered. ofxkozdmhy (xyrwvpbanl ) | - | 15 Nov 2016 | |||